ArticleAmerican journal of nephrology2026
Risks of Major Adverse Kidney Events in Non-Hispanic Black Patients with Diabetes or Hypertension: A Real-World Cohort Study.
Article in American journal of nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic kidney disease (CKD) disproportionately burdens non-Hispanic Black (NHB) patients who experience a three- to four-fold higher risk of kidney failure than non-Hispanic White (NHW) individuals. Diabetes and hypertension are the leading causes of CKD, yet the influence of race, social context, and clinical factors on major adverse kidney events (MAKEs) remains inadequately understood. This study examined relationships between race, social factors, and MAKE among patients with diabetes or hypertension.
methodsElectronic health record data from the CURE-CKD Registry (2013-2022) were used to assemble two mutually exclusive cohorts of NHB and NHW (reference) adults with (1) diabetes (N = 375,605) or (2) hypertension without diabetes (N = 710,768). The primary outcome was time to first MAKE, defined as ≥40% decline in estimated glomerular filtration rate (eGFR), eGFR <15 mL/min/1.73 m2, kidney failure, dialysis, transplant, or death. Cox proportional hazards models estimated associations between predictors and MAKE. Extreme gradient boosting (XGBoost) machine learning (ML) models were used as a complement to the traditional survival models to evaluate variable relationships with MAKE and compare predictive performance.
resultsNHB patients were younger (diabetes: 56 ± 15 vs. 62 ± 14 years; hypertension: 50 ± 16 vs. 59 ± 16 years), had more prevalent CKD (diabetes: 19% vs. 15%; hypertension: 8% vs. 7%), and had higher adjusted MAKE risk than NHW patients (diabetes: HR = 1.07, 95% CI: 1.04-1.11; hypertension: HR = 1.10, 95% CI: 1.06-1.14). MAKE occurred in 24% (n = 90,910) of the diabetes population over a median (interquartile range) of 4.1 (2.0-6.3) years, and 15% (n = 106,209) of the hypertension population over 4.4 (2.4-6.3) years. Non-commercial insurance (Medicaid, Medicare, or unclassified insurance [reference: Commercial]), higher social vulnerability index, more frequent hospitalizations, and urban residence were the top predictors of MAKE. XGBoost outperformed Cox models for MAKE prediction and SHapley Additive exPlanations value rankings confirmed key predictors identified in Cox models.
conclusionAcross two large cohorts for CKD, NHB patients experienced higher MAKE risk, shaped by neighborhood social and structural conditions rather than demographic and clinical characteristics alone. Integrating social risk assessment, improving guideline-directed testing, and using complementary ML and Cox modeling approaches may enhance early identification of CKD risk, support targeted intervention, and reduce disparities in CKD outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.